Sigmund Rogich Net Worth

Sigmund Rogich biography

Sigmund Rogich serves as Director of the Company. Mr. Sigmund “Sig” Rogich is President of The Rogich Communications Group and serves on the Board of Keep Memory Alive, a philanthropic organization which raises awareness about brain disorders and Alzheimer's disease. Keep Memory Alive funds clinical trials through Cleveland Clinic’s Lou Ruvo Center for Brain Health to advance new treatments for patients with Alzheimer’s, Huntington’s and Parkinson’s disease, as well as frontotemporal dementia and multiple sclerosis. Mr. Rogic was formerly the US Ambassador to Iceland. He has served as a senior consultant to candidates for the highest office, including Presidents Ronald Reagan and George H.W.Bush. Mr. Rogich serves on the Board of Directors for many charitable causes.

How old is Sigmund Rogich?

Sigmund Rogich is 68, he's been the Director of BioVie since 2020. There are 2 older and 8 younger executives at BioVie. The oldest executive at BioVie Inc. is Steven Gorlin, 82, who is the Director.

What's Sigmund Rogich's mailing address?

Sigmund's mailing address filed with the SEC is C/O BIOVIE INC., 680 W NYE LANE STE 201, CARSON CITY, NV, 89703.

Insiders trading at BioVie

Over the last 9 years, insiders at BioVie have traded over $352,740 worth of BioVie stock and bought 67,100 units worth $464,015 . The most active insiders traders include Terren S Peizer, Steve Gorlin et Richard J Berman. On average, BioVie executives and independent directors trade stock every 122 days with the average trade being worth of $301,811. The most recent stock trade was executed by Cuong V Do on 4 March 2024, trading 10,000 units of BIVI stock currently worth $28,900.

What does BioVie do?

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.

BioVie executives and stock owners

BioVie executives and other stock owners filed with the SEC include:

• Jonathan M. Adams M.B.A., MBA,
  Exec. VP of Liver Disease Program
• Joanne Wendy Kim CPA,
  CFO & Corp. Sec.
• Cuong Viet Do M.B.A., MBA,
  Pres, CEO & Director
• Mina Sooch,
  Independent Director
• Michael Sherman,
  Independent Director
• James Lang,
  Independent Director
• Hari Kumar,
  Independent Director
• Sigmund Rogich,
  Director
• Rajah Menon,
  Director
• Robert Hariri,
  Director
• Steven Gorlin,
  Director
• Richard Berman,
  Director
• Patrick Yeramian,
  Chief Medical Officer
• Penelope Markham,
  Chief Scientific Officer
• J. Wendy Kim,
  Chief Financial Officer, Corporate Secretary
• Terren Peizer,
  Chief Executive Officer, Director
• Jonathan Adams,
  President, Chief Operating Officer
• Dr. Joseph M. Palumbo M.D.,
  Chief Medical Officer
• Clarence N. Ahlem,
  Exec. VP of Neuroscience Product Devel.
• Dr. Christopher L. Reading Ph.D.,
  Exec. VP of Neuroscience R&D
• Denise Smith,
  Sr. VP of Manufacturing & Devel.
• Dr. Penelope Markham Ph.D.,
  Exec. VP of Liver Disease R&D
• R Richard Wieland,
  interim CFO
• Julie G Anderson,
  Director
• Cuong V Do,
  President & CEO
• Steve Gorlin,
  Director
• Clarence N. Ahlem,
  EVP Neuroscience Product Dev.
• Christopher Reading,
  EVP Neuroscience R&D
• Joseph M Palumbo,
  Chief Medical Officer